DPYD
DPYD is the rate-limiting enzyme for the breakdown of pyrimidines and the primary detoxifier of 5-fluorouracil (5-FU) chemotherapy. Genetic deficiency in DPYD is a major cause of severe, life-threatening toxicity from standard chemotherapy doses.
Key Takeaways
- •DPYD clears over 80% of the chemotherapy drug 5-fluorouracil (5-FU) from the body.
- •Inherited DPYD deficiency is common, affecting 3-5% of the population.
- •Standard chemotherapy doses can be fatal for individuals with DPYD mutations.
- •Pre-treatment screening for DPYD is now a clinical requirement in many oncology guidelines.
Basic Information
- Gene Symbol
- DPYD
- Full Name
- Dihydropyrimidine Dehydrogenase
- Also Known As
- DHPDHPDHASEDPD
- Location
- 1p21.3
- Protein Type
- Pyrimidine Catabolic Enzyme
- Protein Family
- Dihydropyrimidine dehydrogenase family
Related Isoforms
Key SNPs
The most common and severe deficiency variant; causes a splice defect that results in zero functional enzyme. Homozygotes are at extreme risk of fatal 5-FU toxicity.
Ile560Ser; a rare but very severe loss-of-function mutation that leads to profound DPD deficiency and chemotherapy intolerance.
Asp949Val; a moderate risk variant that reduces enzyme activity by ~50%. Requires a 50% reduction in chemotherapy starting dose.
Haplotype B3 variant; a deep intronic variant that creates a cryptic splice site, leading to reduced DPD activity and increased risk of toxicity.
Overview
DPYD (Dihydropyrimidine Dehydrogenase) encodes the initial and rate-limiting enzyme in the catabolic pathway of the pyrimidine bases, uracil and thymine. This enzyme is primarily expressed in the liver, where it acts as a high-capacity filter for both natural pyrimidines and synthetic "fluoropyrimidine" drugs like 5-fluorouracil (5-FU) and capecitabine.
The significance of DPYD is almost entirely centered on its role in oncology. Fluoropyrimidines are the backbone of treatment for colorectal, breast, and head and neck cancers. However, over 80% of the drug is normally destroyed by DPYD before it can reach its target. In individuals with genetic DPYD deficiency, the drug is not cleared, leading to massive build-up and catastrophic toxicity that can damage the gut, bone marrow, and nervous system.
Conceptual Model
A simplified mental model for the pathway:
DPYD ensures that the "solvent" of chemotherapy only stays in the body long enough to kill the tumor.
Core Health Impacts
- • Drug Detoxification: Responsible for the rapid catabolism of fluoropyrimidine chemotherapy agents
- • Pyrimidine Homeostasis: Maintains the systemic balance of uracil and thymine levels
- • Bone Marrow Safety: Prevents the lethal suppression of white blood cells (leukopenia) during treatment
- • Intestinal Integrity: Protects the gut lining from the severe mucositis caused by un-metabolized 5-FU
- • Neurodevelopment: Complete DPD deficiency in children leads to severe neurological impairment and microcephaly
Protein Domains
FMN/FAD Binding Sites
Flavin-binding domains that facilitate the transfer of electrons required for the reduction of pyrimidines.
Iron-Sulfur Clusters
Essential [4Fe-4S] clusters that provide the internal electrical circuit for the enzyme's catalytic cycle.
NADPH Interaction Site
The region that binds the NADPH cofactor needed to provide the reducing power for pyrimidine breakdown.
Upstream Regulators
5-Fluorouracil (5-FU) Activator
The primary clinical substrate; its presence in the blood requires immediate DPYD-mediated clearance.
Capecitabine Activator
An oral pro-drug that is converted to 5-FU, subsequently relying on DPYD for detoxification.
Thymine / Uracil Activator
Endogenous substrates that maintain the baseline activity and turnover of the DPYD enzyme.
Genetic Variants Modulator
The primary determinant of individual DPYD capacity; mutations dictate the "phenotypic speed" of the drain.
Liver Volume Activator
Hepatic mass and blood flow determine the total systemic "clearing power" of the DPYD system.
Downstream Targets
5-FU Detoxification Activates
The conversion of active 5-FU into the non-toxic metabolite dihydrofluorouracil (DHFU).
DHFU Production Activates
The major downstream metabolite; its levels in the blood can be used to track DPYD function.
Thymine Catabolism Activates
The breakdown of thymine into beta-aminoisobutyrate, an essential step in nucleic acid turnover.
Fluorouracil Toxicity Inhibits
In the absence of DPYD, 5-FU levels skyrocket, causing lethal damage to rapidly dividing tissues.
Pyrimidine Homeostasis Activates
The global biological outcome; keeping the building blocks of DNA at safe, manageable levels.
Role in Aging
DPYD function is a major modifier of "oncological resilience" in the elderly. As cancer becomes more common with age, the genetically determined safety of the primary chemotherapy tools (5-FU) is the definitive factor in whether an older patient can tolerate life-extending treatment.
Toxicity Sensitivity
Older patients often have reduced "physiologic reserve," making the drug build-up from DPYD variants even more lethal.
Reduced Organ Flow
Age-related declines in liver and kidney flow can exacerbate the effects of DPYD deficiency, leading to "over-dosing" of chemotherapy.
Hematopoietic Decline
The "anemia of aging" synergizes with DPYD-mediated marrow suppression, leading to severe neutropenia in older adults.
Gut Barrier Thinning
Older individuals are more prone to the life-threatening diarrhea and mucositis caused by failed 5-FU clearance.
Polypharmacy Synergy
While DPYD has few direct drug-drug interactions, the systemic stress of its failure impacts the management of all other geriatric conditions.
Metabolic Decay
The gradual decline in liver enzyme density with age may unmask "moderate" DPYD variants that were silent in youth.
Disorders & Diseases
Fluoropyrimidine Toxicity
The most serious clinical manifestation. Patients with DPYD variants develop grade 3-4 toxicity (mucositis, neutropenia, diarrhea) after just one dose of 5-FU.
DPD Deficiency (Juvenile)
A rare metabolic disorder where children have no DPYD function. Leads to severe developmental delay, seizures, and autism.
Hand-Foot Syndrome
A painful skin reaction to capecitabine that is significantly more frequent and severe in individuals with reduced DPYD activity.
Severe Mucositis
Excruciating inflammation and ulceration of the entire digestive tract caused by the failure to detoxify 5-FU.
Agranulocytosis
The complete disappearance of white blood cells from the blood, a frequent and lethal result of 5-FU build-up in DPYD variants.
The FDA/CPIC Recommendation
In response to the high mortality rate, clinical groups (CPIC) now recommend that all patients undergoing fluoropyrimidine therapy should be screened for the four major DPYD variants to allow for life-saving dose reductions.
Interventions
Supplements
Sometimes used to support gut barrier health during chemotherapy, though it does not address the underlying DPYD deficiency.
Essential for the bone marrow to recover from the suppression caused by chemotherapy build-up.
May provide some support for the gut microbiome after the severe dysbiosis caused by fluoropyrimidine-induced diarrhea.
Studied as a potential competitive substrate to rescue cells from the toxic effects of 5-FU in DPYD failure.
Lifestyle
The most important lifestyle/clinical decision; insisting on a DPYD test before starting any "5-FU" or "Capecitabine" treatment.
Critical during chemo, especially for DPYD carriers who are at extreme risk for sudden, severe neutropenia.
Supports systemic clearance and helps manage the severe diarrhea that characterizes DPYD toxicity flares.
If you are a DPYD carrier, your family members must be notified, as they likely share the same life-threatening vulnerability to chemotherapy.
Medicines
The primary chemotherapy drug whose safety is governed by the DPYD enzyme.
The oral version of 5-FU; carriers of DPYD variants often require a 50-100% reduction in capecitabine dose.
The FDA-approved "antidote" for 5-FU overdose; it can save the lives of DPYD-deficient patients if given within 96 hours of chemotherapy.
An antiviral that is a potent, irreversible inhibitor of DPYD; its use with 5-FU is fatal and strictly prohibited.
Lab Tests & Biomarkers
Genetic Screening
The primary test for the four major variants (*2A, *13, c.2846A>T, and B3). Standard of care in many EU countries.
Comprehensive sequencing used to identify rare or novel mutations in cases of unexplained extreme toxicity.
Functional Markers
A blood test that measures the actual activity of the DPD enzyme in the liver; high uracil indicates deficiency.
A research probe used to measure the total systemic pyrimidine catabolic capacity in real-time.
Therapeutic Monitoring
Measures the cumulative exposure to 5-FU; used to ensure the dose is effective but not toxic.
General markers of liver function that can impact the total DPYD-mediated clearance of medications.
Hormonal Interactions
Cortisol Modulator
Reported to have subtle effects on the background expression levels of hepatic catabolic enzymes.
Estrogen Modulator
May influence the baseline turnover of pyrimidines and the sensitivity of the gut barrier to 5-FU.
Insulin Metabolic Regulator
Supports the general hepatocyte metabolism required for high-capacity drug detoxification.
Growth Hormone Regulator
Required for maintaining the liver mass and enzyme density that provides the DPYD "drain."
Deep Dive
Network Diagrams
DPYD: The Chemotherapy Filter
The Pyrimidine Drain: DPYD and Detoxification
To understand DPYD, one must view the liver as a drainage system for the body’s genetic building blocks. Pyrimidines (uracil and thymine) are the “bricks” used to build RNA and DNA. DPYD is the primary drain that clears the excess bricks from the blood.
The Rate-Limiting Filter: DPYD is the master controller of this pathway. It is a highly complex enzyme that uses iron-sulfur clusters and flavin molecules to perform a difficult chemical reduction. Over 80% of all the pyrimidines in your blood—including the “fake” ones used in chemotherapy—are cleared by this single enzyme.
Chemotherapy Gatekeeper: This enzyme is most famous for its role in cancer treatment. The drugs 5-Fluorouracil (5-FU) and Capecitabine are “fake” pyrimidines designed to poison tumor cells. Because the body sees them as uracil, it tries to clear them through the DPYD drain. The standard doses of these drugs are calculated based on the assumption that a “Normal” drain will destroy most of the medicine before it can cause harm to the patient.
DPYD Deficiency: The Broken Drain
The most critical fact in clinical oncology is that 3-5% of the population has a broken DPYD drain.
*The 2A Variant (rs3918290): This is the most common severe defect. It is a “splice-site” mutation that prevents the cell from building the enzyme correctly. If a patient with this variant is given a standard dose of 5-FU, it is like pouring a gallon of solvent into a sink with a clogged pipe. The drug has nowhere to go.
Lethal Toxicity: The drug builds up to levels 10 to 20 times higher than normal. It begins to kill the rapidly dividing cells of the body: the white blood cells (causing total immune failure), the gut lining (causing severe bloody diarrhea), and the hair follicles. For a patient with a DPYD mutation, standard chemotherapy is not a treatment—it is a lethal poison.
Precision Oncology: The Vistogard Antidote
The tragedy of DPYD is that the toxicity is completely predictable and preventable.
Pre-treatment Screening: By testing a patient’s DNA before the first infusion, doctors can identify the “Broken Drains.” Those with no enzyme function can switch to a different type of chemotherapy, while those with “Slow Drains” can start at a much lower, safer dose.
The Life-Saving Antidote: If an overdose does occur (due to a previously unknown DPYD deficiency), there is now a specific antidote: Vistogard (Uridine Triacetate). This medicine acts as a massive surplus of “real” pyrimidines, which out-competes the chemo drug and allows the patient’s cells to survive the toxic surge. This highlights that DPYD is the definitive safety switch for one of the most common and powerful tools in the fight against cancer.
Practical Note: The Danger of the First Dose
DPYD toxicity is not "cumulative." Unlike many side effects that build up over time, DPYD toxicity often happens with the very first dose. A patient can go from healthy to a life-threatening crisis within days of their first chemo infusion if they have a genetic deficiency.
Dose Reduction is effective. If a person carries a moderate DPYD variant (like rs67376798), they can often still receive 5-FU, but they MUST start at 50% of the normal dose. This "precision start" allows them to get the benefit of the medicine without the risk of lethal toxicity.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The definitive clinical guidelines for using DPYD genetics to prevent chemotherapy-induced mortality.
Large prospective study proving that pre-treatment DPYD screening significantly improves patient safety and reduces hospitalizations.
Characterized the complex iron-sulfur clusters and flavin-binding sites essential for pyrimidine breakdown.
Early work establishing that common variants in DPYD are responsible for the severe toxicity seen in cancer patients.
Demonstrated that screening for DPYD is not only life-saving but also reduces the total cost of cancer care by avoiding ICU admissions.